September 21, 2021 08:00 AM EDT

After selling to Genentech, the old Jecure team is back at an RNA-focused startup — and more enthusiastic than ever

Nicole DeFeudis

Editor

When Genentech swooped in to buy NASH-focused Jecure Therapeutics back in 2018, a handful of the startup’s executives weren’t quite ready to disperse. …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

After selling to Genentech, the old Jecure team is back at an RNA-focused startup — and more enthusiastic than ever

Nicole DeFeudis

Editor

Sign up to read this article for free.

Uro-Oncology Business Manager

ImmunityBio, Inc.

Remote

Pharma's wins and losses in Trump's sprawling executive order on drug prices

US drugs rely heavily on ingredients made overseas, new report shows

Sanofi to pay $125M upfront for two immunology drugs from little-known biotech

Sarepta loses CMO to RNA editing upstart; Another wave of personnel moves at Dyne

Biotech seed rounds sink to lowest level in years as industry slump drags on

New York-based partnership sets the standard for expanding clinical trial access for underserved and diverse ...

Af­ter sell­ing to Genen­tech, the old Je­cure team is back at an RNA-fo­cused start­up — and more en­thu­si­as­tic than ever

Editor

Sign up to read this article for free.

ImmunityBio, Inc.

Remote

After selling to Genentech, the old Jecure team is back at an RNA-focused startup — and more enthusiastic than ever